Open, Controlled, Randomized Study on the Efficacy and Safety of Cefodizime Single Daily DoseversusTwo Daily Doses andversusCeftriaxone Single Daily Dose in Patients with Acute Purulent Bronchitis and Acute Purulent Exacerbation of Chronic Bronchitis
| Autor: | C. Zanussi, G. Cocuzza |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Chronic bronchitis Exacerbation Cefotaxime Injections Intramuscular Drug Administration Schedule Group B law.invention Cefodizime Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Bronchitis Antibacterial agent Pharmacology business.industry Ceftriaxone medicine.disease Cephalosporins Surgery Infectious Diseases Oncology Acute Disease Chronic Disease Female business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 7:535-542 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1179/joc.1995.7.6.535 |
| Popis: | Two hundred and thirty-eight in-patients with signs and symptoms of acute purulent bronchitis or purulent exacerbation of chronic bronchitis at stage 1 and 2 of Anthonisen's classification were enrolled in 11 Centers and randomly assigned to one of the following 3 treatment groups: group A, cefodizime 1 g i.m. qD; group B, cefodizime 1 g i.m. BID; group C, ceftriaxone 1 g i.m. qD. Bacteriological results after treatment were satisfactory in 64 patients (91.4%) of group A, 64 (92.8%) of group B and 74 (94.9%) of group C. Global clinical results after treatment showed satisfactory efficacy in 57 patients (79.2%) of group A, 59 (85.5%) of group B and 63 (80.8%) of group C. There was no statistically significant difference in improvement in single symptoms, global bacteriological or clinical results between the 3 groups. Mild adverse events occurred in only 3 patients (one per group). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|